Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Why Top Pensions Like Verizon and Lockheed Martin are Outsourcing to Goldman James Comtois For Members Only Biopharma Funds Surge on Deals and Drug Breakthroughs Stephen Taub Commercial Real Estate – Navigating the Brave New World of AI Sponsored by Principal